R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Subscribe To Our Newsletter & Stay Updated
